SAM #36C24227Q0003

Sole Source Thyroid Nodule Molecular Diagnostic Testing (ThyroSeq) for Northport VA Medical Center

This notice announces the Department of Veterans Affairs' intent to award a sole source contract for specialized thyroid nodule molecular diagnostic testing at the Northport VA Medical Center. - Agency: Department of Veterans Affairs, Northport VA Medical Center (NCO 2) - Sole source vendor: CYTOPATH BIOPSY LAB INC. - Services required: - Cytopathology evaluation of fine needle aspiration (FNA) samples - Reflex molecular testing - NextGeneration Sequencing (NGS) of DNA and RNA for thyroid nodules - Analysis of thyroid-related mutations, gene fusions, copy number alterations, and expression alterations - Use of the proprietary ThyroSeq Genomic Classifier platform (required for compatibility with existing records and workflows) - Purpose: To ensure continuity of care and clinical performance for veterans with thyroid nodules of indeterminate cytology (AUS/FLUS and related categories) - Period of performance: October 1, 2026 – September 30, 2027, with four option years - No product part numbers or specific quantities provided - This is a notice of intent, not a competitive solicitation - Responses must be submitted via email if interested in future opportunities

Description

No telephone inquiries will be accepted. Northport Veterans Affairs Medical Center (VAMC) requires specialized cytopathology services with comprehensive testing for the evaluation of thyroid nodules with indeterminate cytology Atypia of Undetermined Significance (AUS)/ Follicular Lesion of Undetermined Significance (FLUS) and related categories. This notice does not commit the Government to a contract award, nor does it guarantee any additional information will be provided. All responses to this notice must be emailed to Mariangie.Rivera@va.gov and it must be received no later than Wednesday June 24, 2026, at 10:00 AM EST.

Additional Links:Northport VA Medical Center

View original listing